Xu C, Wan X, Xu L, Weng H, Yan M, Miao M, Sun Y, Xu G, Dooley S, Li Y, Yu C. Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia: one stone hits two birds. J Hepatol. 2015;62:1412–9.
Yu XL, Shu L, Shen XM, Zhang XY, Zheng PF. Gender difference on the relationship between hyperuricemia and nonalcoholic fatty liver disease among Chinese: an observational study. Medicine (Baltimore). 2017;96:e8164.
Lonardo A, Mantovani A, Lugari S, Targher G. Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity. Ann Hepatol. 2020;19:359–66.
Duell PB, Welty FK, Miller M, Chait A, Hammond G, Ahmad Z, Cohen DE, Horton JD, Pressman GS, Toth PP, et al. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the american heart association. Arterioscler Thromb Vasc Biol. 2022;42:e168–85.
Muzurovic E, Peng CC, Belanger MJ, Sanoudou D, Mikhailidis DP, Mantzoros CS. Nonalcoholic fatty liver disease and cardiovascular disease: a review of shared cardiometabolic risk factors. Hypertension. 2022;79:1319–26.
Chung GE, Cho EJ, Yoo JJ, Chang Y, Cho Y, Park SH, Han K, Jeong SM, Yoon KW, Shin DW, et al. Young adults with nonalcoholic fatty liver disease, defined using the fatty liver index, can be at increased risk of myocardial infarction or stroke. Diabetes Obes Metab. 2022;24:465–72.
Kitade H, Chen G, Ni Y, Ota T. Nonalcoholic fatty liver disease and insulin resistance new insights and potential new treatments. Nutrients. 2017. https://doi.org/10.3390/nu9040387.
Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10:330–44.
Zelber-Sagi S, Lotan R, Shlomai A, Webb M, Harrari G, Buch A, Nitzan Kaluski D, Halpern Z, Oren R. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. J Hepatol. 2012;56:1145–51.
Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol. 2005;16:421–7.
Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases [J]. Hepatology. 2018;67(1):328–57.
Chang Y, Jung HS, Cho J, Zhang Y, Yun KE, Lazo M, Pastor-Barriuso R, Ahn J, Kim CW, Rampal S, et al. Metabolically healthy obesity and the development of nonalcoholic fatty liver disease. Am J Gastroenterol. 2016;111:1133–40.
Rotar O, Boyarinova M, Orlov A, Solntsev V, Zhernakova Y, Shalnova S, Deev A, Konradi A, Baranova E, Chazova I, et al. Metabolically healthy obese and metabolically unhealthy non-obese phenotypes in a Russian population. Eur J Epidemiol. 2017;32:251–4.
Stefan N, Schick F, Haring HU. Causes, characteristics, and consequences of metabolically unhealthy normal weight in humans. Cell Metab. 2017;26:292–300.
Eckel N, Muhlenbruch K, Meidtner K, Boeing H, Stefan N, Schulze MB. Characterization of metabolically unhealthy normal-weight individuals: risk factors and their associations with type 2 diabetes. Metabolism. 2015;64:862–71.
Wong WK, Chan WK. Nonalcoholic fatty liver disease: a global perspective. Clin Ther. 2021;43:473–99.
Zhang Q, Lou S, Meng Z, Ren X. Gender and age impacts on the correlations between hyperuricemia and metabolic syndrome in Chinese. Clin Rheumatol. 2011;30:777–87.
Ryu S, Chang Y, Kim SG, Cho J, Guallar E. Serum uric acid levels predict incident nonalcoholic fatty liver disease in healthy Korean men. Metabolism. 2011;60:860–6.
Sirota JC, McFann K, Targher G, Johnson RJ, Chonchol M, Jalal DI. Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: liver ultrasound data from the national health and nutrition examination survey. Metabolism. 2013;62:392–9.
Li Y, Xu C, Yu C, Xu L, Miao M. Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. J Hepatol. 2009;50:1029–34.
Baba T, Amasaki Y, Soda M, Hida A, Imaizumi M, Ichimaru S, Nakashima E, Seto S, Yano K, Akahoshi M. Fatty liver and uric acid levels predict incident coronary heart disease but not stroke among atomic bomb survivors in Nagasaki. Hypertens Res. 2007;30:823–9.
Jaruvongvanich V, Ahuja W, Wijarnpreecha K, Ungprasert P. Hyperuricemia is not associated with severity of liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2017;29:694–7.
Zhou M, Yang N, Xing X, Chang D, Li J, Deng J, Chen Y, Hu C, Zhang R, Lu X, et al. Obesity interacts with hyperuricemia on the severity of non-alcoholic fatty liver disease. BMC Gastroenterol. 2021;21:43.
Wei F, Li J, Chen C, Zhang K, Cao L, Wang X, Ma J, Feng S, Li WD. Higher serum uric acid level predicts non-alcoholic fatty liver disease: A 4-year prospective cohort study. Front Endocrinol (Lausanne). 2020;11:179.
Zhou BF. Cooperative meta-analysis group of the working group on obesity in C: predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults–study on optimal cut-off points of body mass index and waist circumference in Chinese adults. Biomed Environ Sci. 2002;15:83–96.
Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III). JAMA. 2001;285:2486–97.
Wei F, Li J, Chen C, Zhang K, Cao L, Wang X, Ma J, Feng S, Li WD. Higher serum uric acid level predicts non-alcoholic fatty liver disease: a 4-year prospective cohort study. Front Endocrinol (Lausanne). 2020;11:179.
Chen TP, Lin WY, Chiang CH, Shen TH, Huang KC, Yang KC. Metabolically healthy obesity and risk of non-alcoholic fatty liver disease severity independent of visceral fat. J Gastroenterol Hepatol. 2021;36:2903–10.
Zhou J, Zhou F, Wang W, Zhang XJ, Ji YX, Zhang P, She ZG, Zhu L, Cai J, Li H. Epidemiological Features of NAFLD From 1999 to 2018 in China. Hepatology. 2020;71:1851–64.
Younossi ZM. Non-alcoholic fatty liver disease—a global public health perspective. J Hepatol. 2019;70:531–44.
Wu LM, He H, Chen G, Kuang Y, Lin BY, Chen XH, Zheng SS. Associations between obesity and metabolic health with nonalcoholic fatty liver disease in elderly Chinese. Hepatobiliary Pancreat Dis Int. 2020;19:252–7.
Sung KC, Cha SC, Sung JW, So MS, Byrne CD. Metabolically healthy obese subjects are at risk of fatty liver but not of pre-clinical atherosclerosis. Nutr Metab Cardiovasc Dis. 2014;24:256–62.
Vusirikala A, Thomas T, Bhala N, Tahrani AA, Thomas GN, Nirantharakumar K. Impact of obesity and metabolic health status in the development of non-alcoholic fatty liver disease (NAFLD): A United Kingdom population-based cohort study using the health improvement network (THIN). BMC Endocr Disord. 2020;20:96.
Man S, Lv J, Yu C, Deng Y, Yin J, Wang B, Li L, Liu H. Association between metabolically healthy obesity and non-alcoholic fatty liver disease. Hepatol Int. 2022;16(6):1412–1423. https://doi.org/10.1007/s12072-022-10395-8.
Liu P, Ma F, Lou H, Zhu Y, Chen Y. Relationship between normal serum uric acid levels and nonalcoholic fatty liver disease in postmenopausal women. Zhonghua Gan Zang Bing Za Zhi. 2014;22:53–7.
Zheng X, Gong L, Luo R, Chen H, Peng B, Ren W, Wang Y. Serum uric acid and non-alcoholic fatty liver disease in non-obesity Chinese adults. Lipids Health Dis. 2017;16:202.
Bao T, Ying Z, Gong L, Du J, Ji G, Li Z, Gao W, Jiang X, Yang H, Huang Y, Tang H. Association between Serum Uric Acid and nonalcoholic fatty liver disease in nonobese postmenopausal women: a cross-sectional study. Sci Rep. 2020;10:10072.
Zhou Y, Wei F, Fan Y. High serum uric acid and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis. Clin Biochem. 2016;49:636–42.
Khan RS, Bril F, Cusi K, Newsome PN. Modulation of insulin resistance in nonalcoholic fatty liver disease. Hepatology. 2019;70:711–24.
Stefan N, Haring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol. 2019;7:313–24.
Tanase DM, Gosav EM, Costea CF, Ciocoiu M, Lacatusu CM, Maranduca MA, Ouatu A, Floria M. The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD). J Diabetes Res. 2020;2020:3920196.
Smith GI, Mittendorfer B, Klein S. Metabolically healthy obesity: facts and fantasies. J Clin Invest. 2019;129:3978–89.
Barazzoni R, Gortan Cappellari G, Ragni M, Nisoli E. Insulin resistance in obesity: an overview of fundamental alterations. Eat Weight Disord. 2018;23:149–57.
Zhu Y, Hu Y, Huang T, Zhang Y, Li Z, Luo C, Luo Y, Yuan H, Hisatome I, Yamamoto T, Cheng J. High uric acid directly inhibits insulin signalling and induces insulin resistance. Biochem Biophys Res Commun. 2014;447:707–14.
Zhi L, Yuzhang Z, Tianliang H, Hisatome I, Yamamoto T, Jidong C. High uric acid induces insulin resistance in cardiomyocytes in vitro and in vivo. PLoS ONE. 2016;11:e0147737.
Aroor AR, McKarns S, Demarco VG, Jia G, Sowers JR. Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance. Metabolism. 2013;62:1543–52.
Baldwin W, McRae S, Marek G, Wymer D, Pannu V, Baylis C, Johnson RJ, Sautin YY. Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes. 2011;60:1258–69.
Yu P, Huang L, Wang Z, Meng X, Yu X. the association of serum uric acid with beta-cell function and insulin resistance in nondiabetic individuals: a cross-sectional study. Diabetes Metab Syndr Obes. 2021;14:2673–82.
Xu C, Ma Z, Wang Y, Liu X, Tao L, Zheng D, Guo X, Yang X. Visceral adiposity index as a predictor of NAFLD: a prospective study with 4-year follow-up. Liver Int. 2018;38:2294–300.
Finelli C, Tarantino G. Is visceral fat reduction necessary to favour metabolic changes in the liver? J Gastrointestin Liver Dis. 2012;21:205–8.
Dong H, Xu Y, Zhang X, Tian S. Visceral adiposity index is strongly associated with hyperuricemia independently of metabolic health and obesity phenotypes. Sci Rep. 2017;7:8822.